Yahoo Finance reporter Brooke DiPalma breaks down the latest stock market developments as part of this morning's Market ...

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin. Yahoo ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Stock futures are lower, looking to snap a four-day win streak but the market is still headed for its second weekly win ...

Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...

If there's a group even dumber, unfortunately, it would be foreign retail investors. And they're buying U.S. stocks like they're going out of fashion.

I mean when you sit down and you watch these presentations and interactions ... Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that is one of the leading players in the global ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $80.57, reflecting a -0.57% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on the ...

According to Evaluate Pharma, China's growing influence in pharmaceutical R&D is a key theme to watch in 2025. The pharma ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

Trump's call at Davos for cuts to US interest rates, oil prices, and taxes spurred investor optimism for his policies, ...